慢性髓性白血病无治疗缓解管理:GIMEMA CML工作组建议
GIMEMA CML工作组基于德尔菲法在50个中心代表中达成共识,提出以无治疗缓解(TFR)为目标的管理策略。共识涵盖疾病风险评估(ELTS评分)、一线TKI选择、年龄界限及应答标准:3个月BCR-ABL1≤10%、6个月≤1%、12个月≤0.1%、24个月≤0.01%无需换药;反之则需换药。
要点
- 以TFR为目标时,需综合TFR需求、TKI、白血病特征和患者四变量制定策略。
- 采用ELTS评分评估疾病风险,并共识年龄界限用于一线治疗选择。
- 应答标准:3个月BCR-ABL1≤10%、6个月≤1%、12个月≤0.1%、24个月≤0.01%无需换TKI。
核心结论
- GIMEMA CML WP提出的共识建议可能有助于优化以TFR为目标的治疗策略。
研究设计与样本
- 采用类德尔菲法在CML WP的50个中心代表间达成共识。
主要发现
- 共识涉及疾病风险评估(ELTS评分)、一线治疗年龄界限、一线TKI选择及应答定义。
关键数值与推荐
- 无需换TKI的应答:3个月BCR-ABL1≤10%、6个月≤1%、12个月≤0.1%、24个月≤0.01%。
- 需换TKI的应答:3和6个月BCR-ABL1>10%、12个月>1%、24个月>0.1%。
临床怎么用
- 可根据共识的应答标准评估是否需更换TKI,以增加TFR概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, ≤0.1% at 12 months, ≤0.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 >10% at 3 and 6 months, >1% at 12 months, and >0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR.
引用
- Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019. PMID: 31869412. doi:10.1182/bloodadvances.2019000865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。